New ultrasound parameters reflecting kidney function & the effects of phenylphrine after cardiac surgery

Evaluation of patients after cardiac surgery: Novel ultrasound parameters for quantification of renal perfusion & analysis of phenylephrines’ effect on invasive haemodynamics and echocardiographic measures.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-000573-25-DK

Enrollment

Registered

2020-03-20

Start date

2020-03-20

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Interventions

Pharmaceutical Form: Solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Elective cardiac anaesthesia Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria: Insufficient ultrasonographic imaging of the kidneys, known morphological kidney disease, preoperative dialysis, chronic atrial fibrillation, planned mitral valve surgery

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the haemodynamic effects of phenylephrine;Secondary Objective: Not applicable;Primary end point(s): The effects of phenylephrine on the ratio SVR/PVR. ;Timepoint(s) of evaluation of this end point: Before, during af after infusion of phenylephrine (to a target MAP > 20mmHg of baseline)	—

Secondary

Measure	Time frame
Secondary end point(s): The effects of phenylephrine on: - Transoesophageal measurement of left ventricular function (strain, S-max, EF, E/e’) and right ventricular function (TAPSE, S-max, free wall strain, fractional shortening) - Invasive measurements of the systemic and pulmonary circulation (central venous saturation, systolic/diastolic/mean pulmonary- and systemic blood pressure) - Cardiac output, mixed venous saturation.;Timepoint(s) of evaluation of this end point: Before, during af after infusion of phenylephrine (to a target MAP > 20mmHg of baseline)	—

Measure

Time frame

Secondary end point(s): The effects of phenylephrine on: - Transoesophageal measurement of left ventricular function (strain, S-max, EF, E/e’) and right ventricular function (TAPSE, S-max, free wall strain, fractional shortening) - Invasive measurements of the systemic and pulmonary circulation (central venous saturation, systolic/diastolic/mean pulmonary- and systemic blood pressure) - Cardiac output, mixed venous saturation.;Timepoint(s) of evaluation of this end point: Before, during af after infusion of phenylephrine (to a target MAP > 20mmHg of baseline)

—

Countries

Denmark

Contacts

Public ContactDepartment of Anaesthesia

Aarhus University Hospital

peter.juhl-olsen@clin.au.dk

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026